Subtype
Soft Tissue Neoplasm of Uncertain Differentiation
CI-CAN-00001532Explore in graph →
Non-malignant74 active trials2 approved drugs38 evidence items
- NCIt
- C7148
Loading cancer entity…
Subtype
CI-CAN-00001532Explore in graph →
Clinical trials
241 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00563680 | QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors | completed | Phase 2 | 38 | NantCell, Inc.INDUSTRY | 0 | Oct 27, 2016 | clinicaltrials |
| NCT00837148 | Sorafenib and Dacarbazine in Soft Tissue Sarcoma | completed | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00030667 |
| Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood |
| completed |
| Phase 2 |
| 100 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Apr 15, 2015 |
| clinicaltrials |
| NCT00831844 | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 2 | 116 | National Cancer Institute (NCI)NIH | 3 | Mar 30, 2015 | clinicaltrials |
| NCT00331643 | Ixabepilone in Treating Young Patients With Refractory Solid Tumors | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2014 | clinicaltrials |
| NCT01281865 | Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2014 | clinicaltrials |
| NCT00503295 | Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung | completed | Phase 2 | 53 | Oncolytics BiotechINDUSTRY | 1 | Oct 2, 2014 | clinicaltrials |
| NCT00516295 | Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma | completed | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2014 | clinicaltrials |
| NCT00245102 | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | completed | Phase 2 | 147 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00457964 | RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM | completed | Phase 1 / Phase 2 | 36 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Sep 25, 2013 | clinicaltrials |
| NCT01690871 | A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00557609 | Phase 2 Study in Patients With MiT Tumors | completed | Phase 2 | 47 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 3 | Feb 8, 2013 | clinicaltrials |
| NCT00417807 | Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors | completed | Phase 1 / Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 24, 2010 | clinicaltrials |
| NCT00005906 | Treatment With Octreotide in Patients With Lymphangioleiomyomatosis | completed | Phase 2 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 30, 2010 | clinicaltrials |
| NCT00490789 | Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM(TESSTAL) | unknown | Phase 2 | 14 | Cardiff UniversityOTHER | 1 | Apr 30, 2008 | clinicaltrials |
| NCT00457808 | Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM | completed | Phase 2 | 25 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 9, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Oct 27, 2016source: clinicaltrials